IT Transformation and Cloud Content Management for MedTech, Biotechnology and Pharmaceutical Companies

INconnect28 - 29 September 2017, Berlin, Germany.
Due to evolving technology and accelerated growth in research and development activities, cloud computing and IT business technology have increased rapidly. Over the past decades, cloud computing has had profound impact in Life Sciences industry by bringing efficiencies, allowing enterprise-wide agility, and boosting patient outcomes. Cloud computing solutions has reshaped promotional strategies of various Life Science companies and transformed modes of interactions with physicians.

As Life Science sector is currently improving and accelerating its correlation with IT, the Life Sciences Cloud Coalition have moved to the cloud computing and working with their patient through it.

Global Cloud Computing in Life Science Market is expected to expand at a rapid pace during the period of 2015 - 2023 due to the increasing use of cloud computing in Life Science research and development.

This event will serve as a business networking platform as well as a scientific examination of the advantages and disadvantages in implementing IT modernization and cloud computing.

Key Topics

  • Examination of the EU General Data Protection Regulation and practical implementation
  • Analysis of Data security and Privacy Global Outlook
  • Benchmark your IT approach to transformation
  • Understanding the need for Scalability and Flexibility of Cloud Computing
  • IT Infrastructure Modernisation in Pharma and Rea
  • World Implementations
  • Factors driving Digital and Mobile Technologies in Patient Engagement
  • Cloudy 2020: Cloudy Opportunities and Challenges in the future
  • Harmonization of data privacy laws across Europe
  • Discussion of pros and cons of private cloud and public cloud
  • e-commerce trends and application in Cloud

Target Audience

  • Pharmaceutical companies
  • Cloud Content Solution/Software Providers
  • Biotechnology companies
  • Medical Technology companies
  • Research Centers
  • Physicians

For further information, please visit:
http://www.inconnect.net/events/events/it-transformation-and-cloud-content-management-for-medtech-biotechnology-and-pharmaceutical-companies

About INconnect
Academic management research shows that knowledge is a crucial asset for companies concerning sustained competitive advantage. Markets provide opportunities for companies to succeed in organizing themselves around new information on industry trends and technology. Those are the companies that can and will innovate.

Improved technologies and strategies are required for innovation. The only possible fuel for innovation are ideas. Ideas arise when the right people, get the right information, in the right context.

INconnect uses its extensive international network in top-executive event management to bring together industry leaders, lawmakers and experts.

Most Popular Now

Therapy using dual immune system cells effectively…

A newly developed immunotherapy that simultaneously uses modified immune-fighting cells to home in on and attack two antigens, or foreign substances, on cancer cells was ...

How to develop new drugs based on merged datasets

Polymorphs are molecules that have different molecular packing arrangements despite identical chemical compositions. In a recent paper, researchers at GlaxoSmithKline (GS...

New drug combination effective against SARS-CoV-2 …

More countries with greater resources are opening up for a more normal life. But COVID-19 and the SARS-CoV-2 virus are still a significant threat in large parts of the wo...

Cleveland Clinic study suggests steroid nasal spra…

A recent Cleveland Clinic study found that patients who regularly use steroid nasal sprays are less likely to develop severe COVID-19-related disease, including a 20 to 2...

Sanofi to focus its COVID-19 development efforts o…

Recent positive interim results of Sanofi's mRNA-based COVID-19 vaccine candidate Phase 1/2 study confirm the company's platform robust capabilities and strategy in mRNA...

Discovery of mechanics of drug targets for COVID-1…

A team of international researchers, including McGill Professor Stéphane Laporte, have discovered the working mechanism of potential drug targets for various diseases suc...

Phase II/III trial shows Ronapreve™ (casirivimab a…

Roche (SIX: RO, ROG; OTCQX: RHHBY) today confirmed positive data from the phase II/III 2066 study, investigating Ronapreve™ (casirivimab and imdevimab) in patients hospit...

Pfizer and BioNTech receive first U.S. FDA Emergen…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced that the U.S. Food and Drug Administration (FDA) has authorized for emergency use a booster dose of the P...

AZD7442 request for Emergency Use Authorization fo…

AstraZeneca has submitted a request to the US Food and Drug Administration (FDA) for an Emergency Use Authorization (EUA) for AZD7442, its long-acting antibody (LAAB) com...

Pfizer and BioNTech receive CHMP positive opinion …

Pfizer Inc. (NYSE: PFE, "Pfizer") and BioNTech SE (Nasdaq: BNTX, "BioNTech") today announced that the Committee for Medicinal Products for Human Use (CHMP) of the Europea...

Boehringer Ingelheim acquires Abexxa Biologics to …

Boehringer Ingelheim announced the acquisition of Abexxa Biologics Inc., a biopharmaceutical company taking a new approach in the fields of immuno-oncology and oncology r...

GSK welcomes WHO recommendation for broad roll-out…

GlaxoSmithKline (GSK) plc welcomes and applauds the WHO recommendation for the broader deployment of GSK's RTS,S malaria vaccine to reduce childhood illness and deaths fr...